Updates

February 17, 2020February 17, 2020
eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest

Daily treatment with a low dose of eRapa, Emtora Biosciences‘ new formulation of the therapeutic agent rapamycin, was safe and well tolerated, and led ... Read more
February 12, 2020February 12, 2020
UPenn Researchers Awarded $500K Grant to Develop CAR T-cell Therapy for Advanced PC

A research team at the Abramson Cancer Center of the University of Pennsylvania has been awarded a $500,000 grant from the Alliance for Cancer ... Read more
February 11, 2020February 13, 2020
Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical ... Read more
February 10, 2020February 10, 2020
Concerto, Pfizer Expand Data Partnership to Include Prostate, Other Cancers

Concerto HealthAI and Pfizer Oncology are expanding a collaboration using real-world data (RWD) to advance study design to include a range of cancers, including ... Read more
January 31, 2020February 14, 2020
Stony Brook Team Given $4.2M Grant to Expand Promising Work in Advanced Prostate Cancer

Researchers at Stony Brook University have been awarded a five-year, $4.2 million grant from the National Cancer Institute (NCI) to expand work into promising ... Read more

News

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer
January 29, 2020January 30, 2020
The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to ...
News

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer
January 28, 2020February 3, 2020
A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 ...
News

DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests
January 24, 2020February 5, 2020
Six regions in the non-coding parts of the DNA that surround FOXA1, a major ...
News

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo
January 23, 2020January 23, 2020
Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) ...
News

FDA OKs Phase 2b Trial on SUBA-Itraconazole for Metastatic Castration-resistant Prostate Cancer
January 22, 2020February 14, 2020
The U.S. Food and Drug Administration (FDA) has cleared a Phase 2b clinical trial ...
News

FDA Grants Priority Review to Lynparza as Treatment for Mutated Metastatic Castration-resistant Prostate Cancer
January 22, 2020January 22, 2020
The U.S. Food and Drug Administration (FDA) has granted priority review status to an application ...

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

Zuclomiphene Safely Eases Hot Flashes Linked to ADT Use, Phase 2 Trial Reports
January 20, 2020
Interim Phase 2 trial results show that Veru‘s experimental treatment zuclomiphene citrate is well-tolerated ...
Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations
January 16, 2020January 16, 2020
The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) ...
Advaxis Seeks FDA Approval to Begin Phase 1 Trial of its ADXS-504 Immunotherapy for Prostate Cancer
January 15, 2020January 15, 2020
Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests
January 13, 2020January 13, 2020
US Congress Increases Funding for Prostate Cancer Research for FY 2020
January 8, 2020
EMA Committee Favors Extending Use of Erleada for Metastatic Castration-sensitive Prostate Cancer
January 6, 2020January 30, 2020

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows
December 30, 2019January 9, 2020
Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect ...
Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows
December 19, 2019December 19, 2019
FDA Expands Xtandi Approval to Include Metastatic Castration-sensitive Prostate Cancers
December 18, 2019December 18, 2019
Prostate Cancer Campaigns Boost Enrollment in Study to Validate ClarityDX Diagnostic Test in Canada
December 16, 2019December 16, 2019

Blank Family Foundation Donates $1M to Mount Sinai for Prostate Cancer Research
December 12, 2019
The Arthur M. Blank Family Foundation has given $1 million to the Icahn School ...
Lower Prostate Cancer Risk in Diabetics Likely Due to Fewer Biopsies, Not Medications, Study Says
December 11, 2019
Onvansertib Helps Overcome Resistance to Zytiga in mCRPC Patients, Interim Phase 2 Data Show
December 9, 2019

News

High Blood Levels of 2 Hormones May Be Linked to Prostate Cancer Development, Study Says
December 4, 2019
High blood levels of two hormones — insulin-like growth factor-I (IGF-I) and free testosterone — are ...
News

Relugolix Induces Sustained Testosterone Reduction in Advanced PC, HERO Phase 3 Trial Results Show
December 4, 2019December 6, 2019
Treatment with Myovant Sciences’ relugolix induces a long-lasting reduction in testosterone to castrate levels ...
News

Keytruda Shows Promise for Some with Highly Advanced Prostate Cancer in Phase 2 Trial
December 3, 2019January 2, 2020
The immunotherapy Keytruda (pembrolizumab) extended for at least two years the lives of a small ...
News

Enrollment Completed for Phase 3 Trial Testing Provenge in Prostate Cancer Patients on Active Surveillance
November 14, 2019November 14, 2019
Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 ...
News

Phase 1 DRGT-45 Trial Doses First Patient With New Oral Formulation of Abiraterone Acetate
November 13, 2019
A Phase 1 clinical trial testing DRGT-45 — a new oral formulation of abiraterone ...
News

Men with BRCA2 Mutations Should Get Regular PSA Screening, Phase 3 Interim Data Suggest
November 11, 2019
Prostate-specific antigen (PSA) testing — a controversial approach to detecting prostate cancer — spotted ...
News

Use of Assisted Reproduction Techniques Linked to Increased Prostate Cancer Risk, Study Suggests
November 7, 2019November 11, 2019
Men who father children through assisted reproduction techniques, either in vitro fertilization (IVF) or ...
News

$1.8M NIH Award to Support Work into Robotic System Able to Better Detect Prostate Cancer
November 6, 2019
Haichong Zhang, an assistant professor at Worcester Polytechnic Institute, has been given a Director’s Early ...
News

Veru Completes Enrollment for Zuclomiphene Citrate Trial for ADT-Induced Hot Flashes in PC
November 4, 2019
Veru Healthcare has completed patient enrollment for its Phase 2 clinical trial evaluating the ...
News

Prostate Cancer Patients May Benefit from Routine Tumor Genetic Testing, Study Suggests
October 31, 2019
Implementation of routine tumor genetic testing may help identify the approximately 30% of men ...
News

Celebs in Parody Video Urge Support for Movember to Raise Prostate Cancer Awareness
October 30, 2019
In a lighthearted twist on a serious goal of raising awareness and funds for ...
News

Targeted Radiation (SBRT) Can Control Prostate Cancer That Has Spread Slightly, Trial Results Suggest
October 28, 2019
Stereotactic body radiation therapy (SBRT) — a form of targeted, high-dose radiation therapy — ...
News

Prostate Cancer Patients May Safely Skip Radiation Therapy After Surgery, Phase 3 Trial Shows
October 24, 2019October 25, 2019
Men with prostate cancer who undergo surgery have similar long-term outcomes whether they receive ...
News

FDA Grants Breakthrough Device Designation to IsoPSA Blood Test for Early Prostate Cancer Diagnosis
October 23, 2019
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Cleveland ...
News

Radiotherapy Plans Based on Machine Learning Being Used to Treat Localized PC Patients
October 21, 2019
Radiotherapy plans generated with machine learning in the RayStation system are now being used ...
News

Erleada-ADT Combo Increases Survival of mCSPC Patients Without Affecting Quality of Life, Phase 3 Trial Shows
October 17, 2019
Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays ...
News

Long-term Hormone Therapy Does More Harm than Good in Prostate Cancer Patients with Low PSA Levels After Surgery, Analysis Shows
October 16, 2019October 25, 2019
Men who see their prostate cancer returning after surgery see no benefits from adding ...
News

Liproca Depot Shows Promise for Treatment of Early-Stage Prostate Cancer
October 14, 2019October 14, 2019
A new injectable flutamide formulation called Liproca Depot is safe, well-tolerated and shows sustained efficacy ...

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European ... Read more

Subscribe to our mailing list

Pin It on Pinterest